
Noah Tong
Health Payer Reporter at Fierce Healthcare
Staff writer covering health payers for @FierceHealth. Past: @CBJournal, former sports reporter. Based in Chicago. Find me at [email protected]
Articles
-
1 day ago |
fiercehealthcare.com | Noah Tong
A whirlwind week in Congress is continuing today as Department of Health and Human Services Secretary Robert F. Kennedy Jr. meets before two committees to defend its upcoming budget cuts. Ahead of the hearing, leaders at four patient advocacy groups urged the Trump administration to protect funding for biomedical research and disease prevention. “We are at a crossroads right now,” said Russ Paulsen, chief operating officer with UsAgainstAlzheimer’s.
-
1 day ago |
fiercehealthcare.com | Noah Tong
Digital health company Cohere Health has raised $90 million in a series C funding round to bolster research and development opportunities. The round was led by Temasek, an investment firm owned by the Singapore minister for finance. Other investors joining the round are Deerfield Management, Define Ventures, Flare Capital Partners, Longitude Capital and Polaris Partners.
-
2 days ago |
fiercehealthcare.com | Noah Tong
The CMS Innovation Center, responsible for implementing cost-saving pilot payment models, is choosing to base models it prioritizes off three principles, the department announced May 13.
-
2 days ago |
fiercehealthcare.com | Noah Tong
It’s markup week in the House. Starting today, the House Energy and Commerce (E&C) Committee and the Ways and Means Committee will scrutinize text of the proposed reconciliation bill. The legislation will need a simple majority in the House and Senate to pass, but contradictory wishes from the moderate and more conservative wings of the Republican party will make passage difficult. Debate is expected to last hours. In the E&C Committee, most eyes will be on reductions to Medicaid spending.
-
3 days ago |
fiercehealthcare.com | Noah Tong
President Donald Trump will sign an executive order Monday to link the cost of drugs to prices abroad, under a so-called “most favored nation” policy, through a broader set of actions than during his first term. The order is controversial and will earn swift pushback, and likely legal challenges, from the pharmaceutical industry, insurers, providers and PBMs. Executive orders are directives that signal future intent but don’t override federal law.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 697
- Tweets
- 167
- DMs Open
- Yes

RT @InHealthPolicy: FDA To Provide Novavax Update As ACIP Considers COVID Boosters https://t.co/dFK4a4b7We

RT @EricM_Katz: BREAKING: The Veterans Affairs Dept plans to lay off 10s of thousands of employees this year, per a memo sent Tuesday and o…

RT @big_cases: New minute entry in N.H. Indonesian Community Support v. Trump (birthright EO I): Corrective Entry to 56 Memorandum in Suppo…